(19)
(11) EP 3 270 915 A1

(12)

(43) Date of publication:
24.01.2018 Bulletin 2018/04

(21) Application number: 16710952.9

(22) Date of filing: 15.03.2016
(51) International Patent Classification (IPC): 
A61K 31/40(2006.01)
A61K 31/5355(2006.01)
A61P 31/12(2006.01)
 A61K 31/506(2006.01)
A61K 31/7064(2006.01)
(86) International application number:
PCT/EP2016/055484
(87) International publication number:
WO 2016/146598 (22.09.2016 Gazette 2016/38)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 16.03.2015 WO PCT/CN2015/074269
23.03.2015 WO PCT/CN2015/074854
20.07.2015 WO PCT/CN2015/084480
18.02.2016 WO PCT/CN2016/074012

(71) Applicant: F. Hoffmann-La Roche AG
4070 Basel (CH)

(72) Inventors:
  • DAI, Lue
    Shanghai 201203 (CN)
  • GAO, Lu
    Shanghai 201203 (CN)

(74) Representative: Sauer, Frank 
F. Hoffmann-La Roche AG Patent Department Grenzacherstrasse 124
4070 Basel
4070 Basel (CH)

   


(54) COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR